Phase II Clinical andTranslational Study of Everolimus ± Paclitaxel as First-LineTherapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma

Tomi Jun, Noah M. Hahn, Guru Sonpavde, Constantine Albany, Gary R. MacVicar, Ralph Hauke, Mark Fleming, Theodore Gourdin, Bagi Jana, William K. Oh, Patricia Taik, Huan Wang, Ajay Ramakrishnan Varadarajan, Andrew Uzilov, Matthew D. Galsky

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Treatment options have been historically limited for cisplatin-ineligible patients with advanced urothelial carcinoma (UC). Given the need for alternatives to platinum-based chemotherapy, including non-chemotherapy regimens for patients with both impaired renal function and borderline functional status, in 2010 (prior to the immune checkpoint blockade era in metastatic UC), we initiated a phase II trial to test the activity of everolimus or everolimus plus paclitaxel in the cisplatin-ineligible setting. Methods: This was an open-label phase II trial conducted within the US-based Hoosier Cancer Research Network (ClinicalTrials.gov number: NCT01215136). Patients who were cisplatin-ineligible with previously untreated advanced UC were enrolled. Patients with both impaired renal function and poor performance status were enrolled into cohort 1; patients with either were enrolled into cohort 2. Patients received everolimus 10 mg daily alone (cohort 1) or with paclitaxel 80 mg/m2 on days 1, 8, and 15 of each 28-day cycle (cohort 2). The primary outcome was clinical benefit at 4 months. Secondary outcomes were adverse events, progression-free survival (PFS), and 1-year overall survival (OS). Exploratory endpoints included genomic correlates of outcomes. The trial was not designed for comparison between cohorts. Results: A total of 36 patients were enrolled from 2010 to 2018 (cohort 1, N = 7; cohort 2, N = 29); the trial was terminated due to slow accrual. Clinical benefit at 4 months was attained by 0 (0%, 95% confidence interval [CI] 0-41.0%) patients in cohort 1 and 11 patients (37.9%, 95% CI 20.7-57.7%) in cohort 2. Median PFS was 2.33 (95% CI 1.81-Inf) months in cohort 1 and 5.85 (95% CI 2.99-8.61) months in cohort 2. Treatment was discontinued due to adverse events for 2 patients (29%) in cohort 1 and 11 patients (38%) in cohort 2. Molecular alterations in microtubule associated genes may be associated with treatment benefit but this requires further testing. Conclusion: Everolimus plus paclitaxel demonstrates clinical activity in cisplatin-ineligible patients with metastatic UC, although the specific contribution of everolimus cannot be delineated. Patients with both impaired renal function and borderline functional status may be difficult to enroll to prospective trials. (ClinicalTrials.gov Identifier NCT01215136).

Original languageEnglish
Pages (from-to)E432-E452
JournalOncologist
Volume27
Issue number6
DOIs
StatePublished - Jun 2022

Keywords

  • cisplatin-ineligible
  • everolimus
  • genomic
  • paclitaxel
  • urothelial cancer

Fingerprint

Dive into the research topics of 'Phase II Clinical andTranslational Study of Everolimus ± Paclitaxel as First-LineTherapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma'. Together they form a unique fingerprint.

Cite this